In re Meyer

688 F.2d 789, 215 U.S.P.Q. (BNA) 193, 1982 CCPA LEXIS 103
CourtCourt of Customs and Patent Appeals
DecidedSeptember 16, 1982
DocketAppeal No. 82-510
StatusPublished
Cited by31 cases

This text of 688 F.2d 789 (In re Meyer) is published on Counsel Stack Legal Research, covering Court of Customs and Patent Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Meyer, 688 F.2d 789, 215 U.S.P.Q. (BNA) 193, 1982 CCPA LEXIS 103 (ccpa 1982).

Opinion

MILLER, Judge.

This is an appeal from a decision of the Patent and Trademark Office (“PTO”) Board of Appeals (“board”) sustaining the examiner’s rejection under 35 U.S.C. § 101 of all claims in application serial No. 465,-574, filed April 30, 1974, entitled “Process and Apparatus for Identifying Locations of Probable Malfunction.” We affirm.

BACKGROUND

Appellants in their brief to this court describe their invention, in pertinent part, as follows:

The invention is a process and an apparatus for carrying out the process of testing a complex system and analyzing the results of these tests. The process proceeds by (1) dividing the complex system into a plurality of “elements” and (2) associating a factor of function or malfunction with each of these elements. The factors, which are initialized at the outset, are updated or modified during the course of the process in dependence upon the responses of this system to a series of tests. When the tests have been completed, the resultant factors so produced indicate a measure of probability of function or malfunction of the elements with which they are associated.

The term “elements” is used ... to identify any arbitrary subdivision of the complex system. For example, the complex system may be divided into a plurality of volume elements of uniform, or even nonuniform size. Where the complex system is a portion of the nervous system of a human body, each of the volume-elements may contain various neurogenerators and/or portions of neuropathways. Alternatively, each element of the complex system may constitute a “functional component,” or a portion or a set of functional components of the system. The term “functional component”, as used in the Application and in this Brief, is intended to denote any component of the complex system which is operative to produce, transmit, receive, or store signals or information. In the nervous system, the functional components include the neuro[791]*791generators and neuropathways. Thus, the elements into which the nervous system is divided may be individual neurogenerators and/or neuropathways, or may be portions of sets thereof.

For a given complex system, a table may be compiled of the possible responses or outcomes of the various tests. Each test outcome necessarily falls into one of the following categories:

(a) A specific set of system elements is functioning.

(b) Malfunction is likely to be present in a specific set of system elements; function of another specific set of system elements may also be indicated.

(e) The test outcome has no interpretative significance and no inference can be made concerning function or malfunction of the system elements.

For example, as part of a clinical neurological examination, a patient may be asked to close both his eyes (test). Given this test, the patient may respond in one of three ways (test outcome):

(1) The patient closes both his eyes;
(2) The patient closes his right eye only; or
(3) The patient does not close either eye.

These three test outcomes fall, respectively, into the three categories (a), (b) and (c) described above. Test outcome (1) shows that a specific set of elements (e.g., volume elements containing neurogenerators and pathways) of the nervous system is functioning. Test outcome (2) indicates a malfunction in one or more specific sets of elements (e.g., the volume elements containing those neuropathways leading to the left eyelid). On the other hand, test outcome (2) also shows that certain elements of the nervous system are functioning (e.g., those volume elements containing neuropathways leading to the right eyelid). The test outcome (3) is an example of a response for which no inference can be made. The patient may be deaf, may not understand the language or other unknown factors may be present which remove the interpretative significance of the test outcome.

A realistic computation of malfunction probabilities for all elements in a complex system, based on a large number of test outcomes, is a rather complex task. This problem may be avoided by using a rather simple algorithm to locate elements of probable function and malfunction in a complex system....

Pursuant to the algorithm, each element of the complex system is identified by some suitable code. For the purpose of illustration, let there be K elements designated by numbers k = 1,... ,K. A “function factor” NF(k) and a “malfunction factor” M(k) are associated with each element k. Initially the function factor NF(k) and the malfunction factor M(k) are set equal to zero for all k = 1,... ,K. Whenever a test outcome indicates function or malfunction in certain ones of the elements, NF(k) or M(k), respectively, are incremented by some value or set of values for all the elements k involved.

When an element k is described herein as “functioning” or “malfunctioning”, it will be understood that, in reality, it is one or more of the functional components contained in the element which is either functioning or malfunctioning.

Each outcome of each test applied to the complex system is also identified by some suitable code. For the purpose of illustration, for all the tests performed let there be a total of I test outcomes considered; these are designated by numbers i = 1,... ,1.

For each possible test outcome i in categories (a) or (b) there is a set ^ (i) of elements k which are functioning and/or a set77l(i) of elements k which are malfunctioning. For all values of k in the set y (i) let there be an incrementation factor of probable function ANF(i,k), and for all the values of k in the set77£(i) let there be an incrementation factor of probable malfunction AM(i,k). These incrementation factors, as indicated, may be a function of the test outcome i as well as the elements k with which they are associated. If and when the test outcome i should occur, the [792]*792function factors NK(k) and the malfunction factors M(k) are increased by the incrementation factors ANF(i,k) and AM(i,k) for the elements in the sets ^ (i) and ?7¿(i), respectively.

... [T]he algorithm begins by initializing the function factors NF(k) and malfunction factors M(k) to zero for all elements: i.e., NF(k) = 0 and M(k) = 0 for all k = 1,... ,K. Thereafter, a series of tests is applied to the complex system and the test outcomes that occur are read into the computer. Since I is the total number of possible test outcomes considered, the number N of test outcomes that do occur during an entire examination will be less than I.

During or after the examination, the computer compares each of the N test outcomes that have occurred with its prestored data giving the inference, if any, which can be made from each test outcome.

Let i(n) be the nth of these test outcomes considered by the computer. If no inference from this test outcome i = i(n) is indicated — that is, this test outcome belongs in category (c) — the next test outcome i = i(n + 1) is considered. If the test outcome i = i(n) indicates any set (i) of elements k are functioning, then the function factors NK(k) for all elements k in the set ^ (i) are increased by the previously stored incrementation factors of probable function NF(i, k).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

SmartGene, Inc. v. Advanced Biological Laboratories, SA
555 F. App'x 950 (Federal Circuit, 2014)
Smartgene, Inc. v. Advanced Biological Laboratories, SA
915 F. Supp. 2d 69 (D.C. Circuit, 2013)
Smartgene, Inc. v. Advanced Biological Laboratories, Sa
852 F. Supp. 2d 42 (District of Columbia, 2012)
CyberSource Corp. v. Retail Decisions, Inc.
654 F.3d 1366 (Federal Circuit, 2011)
BANCORP SERVICES v. Sun Life Assur. Co. of Canada
771 F. Supp. 2d 1054 (E.D. Missouri, 2011)
In Re Comiskey [Revised]
Federal Circuit, 2009
In Re Comiskey
554 F.3d 967 (Federal Circuit, 2009)
In Re Bilski
545 F.3d 943 (Federal Circuit, 2008)
In Re Thomas P.H. Warmerdam and Bernard J.H. Verwer
33 F.3d 1354 (Federal Circuit, 1994)
In Re Rex D. Schrader and Eugene D. Klingaman
22 F.3d 290 (Federal Circuit, 1994)
In Re Donaldson Company, Inc
16 F.3d 1189 (Federal Circuit, 1994)
Messerschmidt v. United States
29 Fed. Cl. 1 (Federal Claims, 1993)
In Re Ralph R. Grams and Dennis C. Lezotte
888 F.2d 835 (Federal Circuit, 1989)
In Re Max A. Gulack
703 F.2d 1381 (Federal Circuit, 1983)

Cite This Page — Counsel Stack

Bluebook (online)
688 F.2d 789, 215 U.S.P.Q. (BNA) 193, 1982 CCPA LEXIS 103, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-meyer-ccpa-1982.